Evaluation of interleukin 6 (IL-6) and interleukin 8 (IL-8) as prognosis factors in Coronavirus disease (COVID-19)
Researcher Bulletin of Medical Sciences,
Vol. 28 No. 1 (2023),
9 January 2024
,
Page e1
Abstract
Background and Objective: Better understanding of immunopathogenesis and finding the relationship between disease severity and some cytokines, is an introduction to further research on new biological drugs with the specific aim of obtaining these cytokines can be provided. The present study was performed to determine the ratios of IL-6 and IL-8 (IL-6, IL-8) in Iranian patients with COVID-19.
Materials and Methods: One of our goals is to find a relationship between serums levels of hypothetical cytokines involved in the severity of COVID-19 disease by measuring the serum concentrations of these cytokines in COVID-19 patients at baseline as a prognostic factor.
Results: Regarding right lung involvement as well as involvement of both lungs, there was a significant difference between patients with severe and mild disease severity (p-value <0.001). Ferritin levels were significantly higher in the severely ill group than in the mildly ill group (p-value = 0.003). CRP levels were higher than normal in 93.3% of patients in the present study. CRP levels were not associated with disease severity but were effective in predicting the disease. ESR level was higher than normal in 88% of patients and was effective in prognosis the disease. The mean serum level of interleukin-8 in 38 severe patients was significantly higher than the mean serum level of interleukin 8 in 21 mild patients (p-value <0.001). Death was reported in 11 patients (18.6%). Mortality rate and disease severity showed a significant relationship (p-value = 0.006). The disease was significantly more severe in patients with positive PCR (p-value = 0.026).
Conclusions: In several patients, the serum level of interleukin 8 has been a good evaluator of disease prognosis. Symptoms of COVID-19 may be due to elevated levels of interleukin-8 and its receptor. Therefore, it is suggested that in future studies, interleukin 8 receptor mRNA be tested for the discovery of new biological drugs against COVID-19.
- Prognosis; Interleukin 6 (IL-6), Interleukin 8 (IL-8); COVID-19
How to Cite
References
Zhang, Haibo, et al. "Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target." Intensive care medicine 46.4 (2020): 586-590.
Zhou, Peng, et al. "A pneumonia outbreak associated with a new coronavirus of probable bat origin." nature 579.7798 (2020): 270-273.
World Health Organization. "Novel coronavirus situation report-2. January 22, 2020." (2020).
Li, Qun, et al. "Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia." New England journal of medicine (2020).
Nikolich-Zugich, Janko, et al. "SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes." Geroscience 42.2 (2020): 505-514.
CDC (2020). Coronavirus Disease 2019 (COVID-19). Centers for Disease Control and Prevention, https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-managementpatients. html.
Laguna-Goya, Rocio, et al. "IL-6–based mortality risk model for hospitalized patients with COVID-19." Journal of Allergy and Clinical Immunology 146.4 (2020): 799-807.
Dionigi, R., et al. "Effects of surgical trauma of laparoscopic vs. open cholecystectomy." Hepato-gastroenterology 41.5 (1994): 471-476.
Zahorec, R. "Ratio of neutrophil to lymphocyte counts-rapid and simple parameter of systemic inflammation and stress in critically ill." Bratislavske lekarske listy 102.1 (2001): 5-14.
Pang, Junxiong, et al. "Potential rapid diagnostics, vaccine and therapeutics for 2019 novel coronavirus (2019-nCoV): a systematic review." Journal of clinical medicine 9.3 (2020): 623.
Prompetchara, Eakachai, Chutitorn Ketloy, and Tanapat Palaga. "Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic." Asian Pac J Allergy Immunol 38.1 (2020): 1-9.
Pan, Feng, et al. "Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia." Radiology (2020).
Shi, Heshui, et al. "Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study." The Lancet infectious diseases 20.4 (2020): 425-434.
Chen, Nanshan, et al. "Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study." The lancet 395.10223 (2020): 507-513.
Liu, Jing, et al. "Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients." EBioMedicine 55 (2020): 102763.
Zheng, Jun. "SARS-CoV-2: an emerging coronavirus that causes a global threat." International journal of biological sciences 16.10 (2020): 1678.
Verity, Robert, et al. "Estimates of the severity of coronavirus disease 2019: a model-based analysis." The Lancet infectious diseases 20.6 (2020): 669-677.
Nikpouraghdam, Mohamad, et al. "Epidemiological characteristics of coronavirus disease 2019 (COVID-19) patients in IRAN: A single center study." Journal of Clinical Virology 127 (2020): 104378.
Wan, Suxin, et al. "Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP)." MedRxiv (2020).
- Abstract Viewed: 118 times